Quark Becomes Latest RNAi Drug Developer To Score Big Pharma Support With Pfizer Deal (GenomeWeb News)
December 16th, 2009
Quark Biotech announced this week that it has landed the world’s biggest pharmaceutical firm as a partner, exclusively licensing its proprietary human gene target RTP-801 to Pfizer for certain indications including age-related macular degeneration.
Original post by macular degeneration – Google News
(click on the author/publication link above to see full post)